{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:45:40Z","timestamp":1792028740848,"version":"4.4.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Dopaminergic scintigraphic imaging is a cornerstone to support the diagnosis in dementia with Lewy bodies. To clarify the current state of knowledge on this imaging modality and its impact on clinical diagnosis, we performed an updated systematic review of the literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This systematic review was carried out according to PRISMA guidelines. A comprehensive computer literature search of PubMed\/MEDLINE, EMBASE, and Cochrane Library databases for studies published through June 2022 was performed using the following search algorithm: (a) \"Lewy body\" [TI] OR \"Lewy bodies\" [TI] and (b) (\"DaTscan\" OR \"ioflupane\" OR \"123ip\" OR \"123?ip\" OR \"123 ip\" OR \"123i-FP-CIT\" OR \"FPCIT\" OR \"FP-CIT\" OR \"beta?CIT\" OR \"beta CIT\" OR \"CIT?SPECT\" OR \"CIT SPECT\" OR \"Dat?scan*\" OR \"dat scan*\" OR \"dat?spect*\" OR \"SPECT\"). Risk of bias and applicability concerns of the studies were evaluated using the QUADAS-2 tool.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We performed a qualitative analysis of 59 studies. Of the 59 studies, 19 (32%) addressed the diagnostic performance of dopamine transporter imaging, 15 (25%) assessed the identification of dementia with Lewy bodies in the spectrum of Lewy body disease and 18 (31%) investigated the role of functional dopaminergic imaging in distinguishing dementia with Lewy bodies from other dementias. Dopamine transporter loss was correlated with clinical outcomes in 19 studies (32%) and with other functional imaging modalities in 15 studies (25%). Heterogeneous technical aspects were found among the studies through the use of various radioligands, the more prevalent being the [123I]N\u2011\u03c9\u2011fluoropropyl\u20112\u03b2\u2011carbomethoxy\u20113\u03b2\u2011(4\u2011iodophenyl) nortropane (<jats:sup>123<\/jats:sup>I-FP-CIT) in 54 studies (91.5%). Image analysis used visual analysis (9 studies, 15%), semi-quantitative analysis (29 studies, 49%), or a combination of both (16 studies, 27%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our systematic review confirms the major role of dopaminergic scintigraphic imaging in the assessment of dementia with Lewy bodies. Early diagnosis could be facilitated by identifying the prodromes of dementia with Lewy bodies using dopaminergic scintigraphic imaging coupled with emphasis on clinical neuropsychiatric symptoms. Most published studies use a semi-quantitative analytical assessment of tracer uptake, while there are no studies using quantitative analytical methods to measure dopamine transporter loss. The superiority of a purely quantitative approach to assess dopaminergic transmission more accurately needs to be further clarified.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06154-y","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T09:03:41Z","timestamp":1678871021000},"page":"1988-2035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review"],"prefix":"10.1007","volume":"50","author":[{"given":"Mario","family":"Jreige","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Perriraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jevita","family":"Potheegadoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fosco","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Stampacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Blanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffa","family":"Alessandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemie","family":"Lejay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Salvioni","family":"Chiabotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Nicod Lalonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Allali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1429-1374","authenticated-orcid":false,"given":"John O.","family":"Prior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"6154_CR1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/mds.20535","volume":"20","author":"F Geser","year":"2005","unstructured":"Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: State of the art. Mov Disord. 2005;20:S11\u201320.","journal-title":"Mov Disord."},{"key":"6154_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","volume":"386","author":"Z Walker","year":"2015","unstructured":"Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386:1683\u201397.","journal-title":"Lancet"},{"key":"6154_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"6154_CR4","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","volume":"47","author":"S Morbelli","year":"2020","unstructured":"Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885\u2013912.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6154_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","volume":"19","author":"J-P Taylor","year":"2020","unstructured":"Taylor J-P, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19:157\u201369.","journal-title":"Lancet Neurol"},{"key":"6154_CR6","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s00259-019-04480-8","volume":"47","author":"T Nihashi","year":"2020","unstructured":"Nihashi T, Ito K, Terasawa T. Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis. Eur J Nucl Med Mol Imaging. 2020;47:1984\u201397.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6154_CR7","first-page":"n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:n71.","journal-title":"BMJ"},{"key":"6154_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529.","journal-title":"Ann Intern Med"},{"key":"6154_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1097\/MNM.0000000000001102","volume":"40","author":"V Gupta","year":"2019","unstructured":"Gupta V, Verma R, Ranjan R, Belho ES, Seniaray N, Dinand V, et al. Metabolic imaging patterns in posterior cortical atrophy and Lewy body dementia. Nucl Med Commun. 2019;40:1275\u201382.","journal-title":"Nucl Med Commun"},{"key":"6154_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/mds.27945","volume":"35","author":"M Huber","year":"2020","unstructured":"Huber M, Beyer L, Prix C, Sch\u00f6necker S, Palleis C, Rauchmann B, et al. Metabolic correlates of dopaminergic loss in dementia with Lewy bodies. Mov Disord. 2020;35:595\u2013605.","journal-title":"Mov Disord"},{"key":"6154_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pscychresns.2017.09.007","volume":"269","author":"T Iizuka","year":"2017","unstructured":"Iizuka T, Kameyama M. Metabolic correlate of memory-deficit awareness in dementia with Lewy bodies: implication in cortical midline structure. Psychiatry Res Neuroimaging. 2017;269:43\u20137.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"6154_CR12","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","volume":"50","author":"SM Lim","year":"2009","unstructured":"Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18 F-FDG PET cingulate island sign and comparison to 123 I-\u03b2-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638\u201345.","journal-title":"J Nucl Med"},{"key":"6154_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2020.12.009","volume":"99","author":"T Miyagawa","year":"2021","unstructured":"Miyagawa T, Przybelski SA, Maltais D, Min H-K, Jordan L, Lesnick TG, et al. The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer\u2019s disease dementia. Neurobiol Aging. 2021;99:11\u20138.","journal-title":"Neurobiol Aging"},{"key":"6154_CR14","doi-asserted-by":"publisher","first-page":"102791","DOI":"10.1016\/j.nicl.2021.102791","volume":"32","author":"N Nicastro","year":"2021","unstructured":"Nicastro N, Stripeikyte G, Assal F, Garibotto V, Blanke O. Premotor and fronto-striatal mechanisms associated with presence hallucinations in dementia with Lewy bodies. NeuroImage Clin. 2021;32:102791.","journal-title":"NeuroImage Clin"},{"key":"6154_CR15","doi-asserted-by":"publisher","first-page":"e1180","DOI":"10.1212\/WNL.0000000000011454","volume":"96","author":"Q Chen","year":"2021","unstructured":"Chen Q, Lowe VJ, Boeve BF, Przybelski SA, Miyagawa T, Senjem ML, et al. \u03b2-Amyloid PET and 123 I-FP-CIT SPECT in mild cognitive impairment at risk for Lewy body dementia. Neurology. 2021;96:e1180\u20139.","journal-title":"Neurology"},{"key":"6154_CR16","doi-asserted-by":"publisher","first-page":"540291","DOI":"10.3389\/fneur.2020.540291","volume":"11","author":"Y Inagawa","year":"2020","unstructured":"Inagawa Y, Kanetaka H, Tsugawa A, Sakurai S, Serisawa S, Shimizu S, et al. Efficacy of olfactory and pareidolia tests compared with that of indicative biomarkers in diagnosis of dementia with Lewy bodies. Front Neurol. 2020;11:540291.","journal-title":"Front Neurol"},{"key":"6154_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/psyg.12227","volume":"17","author":"S Kobayashi","year":"2017","unstructured":"Kobayashi S, Makino K, Hatakeyama S, Ishii T, Tateno M, Iwamoto T, et al. The usefulness of combined brain perfusion single-photon emission computed tomography, dopamine-transporter single-photon emission computed tomography, and 123 I-metaiodobenzylguanidine myocardial scintigraphy for the diagnosis of dementia with Lewy bodies: The usefulness of neuroimaging for DLB. Psychogeriatrics. 2017;17:247\u201355.","journal-title":"Psychogeriatrics"},{"key":"6154_CR18","doi-asserted-by":"publisher","first-page":"119998","DOI":"10.1016\/j.jns.2021.119998","volume":"430","author":"A Nakahara","year":"2021","unstructured":"Nakahara A, Sengoku R, Umehara T, Matsuno H, Yamazaki M, Oka H. Frontal lobe dysfunction is associated with reduced DAT-SPECT accumulation in Lewy body disease. J Neurol Sci. 2021;430:119998.","journal-title":"J Neurol Sci"},{"key":"6154_CR19","doi-asserted-by":"publisher","first-page":"e2801","DOI":"10.1212\/WNL.0000000000012060","volume":"96","author":"G Roberts","year":"2021","unstructured":"Roberts G, Durcan R, Donaghy PC, Lawley S, Ciafone J, Hamilton CA, et al. Accuracy of cardiac innervation scintigraphy for mild cognitive impairment with Lewy bodies. Neurology. 2021;96:e2801\u201311.","journal-title":"Neurology"},{"key":"6154_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12149-020-01464-9","volume":"34","author":"F Sakamoto","year":"2020","unstructured":"Sakamoto F, Shiraishi S, Ogasawara K, Tsuda N, Nakagawa M, Tomiguchi S, et al. A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index. Ann Nucl Med. 2020;34:415\u201323.","journal-title":"Ann Nucl Med"},{"key":"6154_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s00259-015-3146-y","volume":"43","author":"S Shimizu","year":"2016","unstructured":"Shimizu S, Hirao K, Kanetaka H, Namioka N, Hatanaka H, Hirose D, et al. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43:184\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6154_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/ggi.12794","volume":"17","author":"S Shimizu","year":"2017","unstructured":"Shimizu S, Kanetaka H, Hirao K, Fukasawa R, Namioka N, Hatanaka H, et al. Neuroimaging for diagnosing dementia with Lewy bodies: what is the best neuroimaging technique in discriminating dementia with Lewy bodies from Alzheimer\u2019s disease?: Neuroimaging for diagnosing DLB. Geriatr Gerontol Int. 2017;17:819\u201324.","journal-title":"Geriatr Gerontol Int"},{"key":"6154_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/ana.24717","volume":"80","author":"P Tiraboschi","year":"2016","unstructured":"Tiraboschi P, Corso A, Guerra UP, Nobili F, Piccardo A, Calcagni ML, et al. 123 I-2\u03b2-carbomethoxy-3\u03b2-(4-iodophenyl)- N -(3-fluoropropyl) nortropane single photon emission computed tomography and 123 I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study. Ann Neurol. 2016;80:368\u201378.","journal-title":"Ann Neurol"},{"key":"6154_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1552-6569.2012.00774.x","volume":"24","author":"G Treglia","year":"2014","unstructured":"Treglia G, Cason E, Cortelli P, Gabellini A, Liguori R, Bagnato A, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 Ioflupane single photon emission computed tomography in Lewy Body diseases: complementary or alternative techniques?: MIBG and FP-CIT Scintigraphy in Lewy Body Diseases. J Neuroimaging. 2014;24:149\u201354.","journal-title":"J Neuroimaging"},{"key":"6154_CR25","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1017\/S1041610208007709","volume":"20","author":"SJ Colloby","year":"2008","unstructured":"Colloby SJ, Firbank MJ, Pakrasi S, Lloyd JJ, Driver I, McKeith IG, et al. A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer\u2019s disease and dementia with Lewy bodies. Int Psychogeriatr. 2008;20:1124.","journal-title":"Int Psychogeriatr"},{"key":"6154_CR26","doi-asserted-by":"crossref","unstructured":"Iwabuchi Y, Shiga T, Kameyama M, Miyazawa R, Seki M, Ito D, et al. Striatal dopaminergic depletion pattern reflects pathological brain perfusion changes in lewy body diseases. Mol Imaging Biol [Internet]. 2022 [cited 2022 Jul 4]; Available from:\u00a0https:\/\/link.springer.com\/10.1007\/s11307-022-01745-x","DOI":"10.1007\/s11307-022-01745-x"},{"key":"6154_CR27","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1007\/s00259-005-1830-z","volume":"32","author":"SJ Colloby","year":"2005","unstructured":"Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O\u2019Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging. 2005;32:1176\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6154_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.neuroimage.2004.06.045","volume":"23","author":"SJ Colloby","year":"2004","unstructured":"Colloby SJ, O\u2019Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, et al. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer\u2019s disease and Parkinson\u2019s disease. NeuroImage. 2004;23:956\u201366.","journal-title":"NeuroImage"},{"key":"6154_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.nicl.2018.04.009","volume":"19","author":"M Joling","year":"2018","unstructured":"Joling M, Vriend C, van der Zande JJ, Lemstra AW, van den Heuvel OA, Booij J, et al. Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson\u2019s disease compared with dementia with Lewy bodies. NeuroImage Clin. 2018;19:130\u20136.","journal-title":"NeuroImage Clin"},{"key":"6154_CR30","doi-asserted-by":"publisher","first-page":"101755","DOI":"10.1016\/j.nicl.2019.101755","volume":"22","author":"M Joling","year":"2019","unstructured":"Joling M, Vriend C, Raijmakers PGHM, van der Zande JJ, Lemstra AW, Berendse HW, et al. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson\u2019s disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study. NeuroImage Clin. 2019;22:101755.","journal-title":"NeuroImage Clin"},{"key":"6154_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00234-016-1773-z","volume":"59","author":"K Kamagata","year":"2017","unstructured":"Kamagata K, Nakatsuka T, Sakakibara R, Tsuyusaki Y, Takamura T, Sato K, et al. Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study. Neuroradiology. 2017;59:89\u201398.","journal-title":"Neuroradiology"},{"key":"6154_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00259-016-3466-6","volume":"44","author":"K Kasanuki","year":"2017","unstructured":"Kasanuki K, Iseki E, Ota K, Kondo D, Ichimiya Y, Sato K, et al. 123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2017;44:358\u201365.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6154_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.clineuro.2016.05.009","volume":"146","author":"G Lamotte","year":"2016","unstructured":"Lamotte G, Morello R, Lebasnier A, Agostini D, Bouvard G, De La Sayette V, et al. Influence of education on cognitive performance and dopamine transporter binding in dementia with Lewy bodies. Clin Neurol Neurosurg. 2016;146:138\u201343.","journal-title":"Clin Neurol Neurosurg"},{"key":"6154_CR34","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1136\/jnnp-2012-302577","volume":"83","author":"S Morgan","year":"2012","unstructured":"Morgan S, Kemp P, Booij J, Costa DC, Padayachee S, Lee L, et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry. 2012;83:1063\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6154_CR35","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1097\/RLU.0000000000001477","volume":"42","author":"N Nicastro","year":"2017","unstructured":"Nicastro N, Garibotto V, Allali G, Assal F, Burkhard PR. Added value of combined semi-quantitative and visual [123I]FP-CIT SPECT analyses for the diagnosis of dementia with Lewy bodies. Clin Nucl Med. 2017;42:e96\u2013102.","journal-title":"Clin Nucl Med"},{"key":"6154_CR36","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1001\/archneur.61.6.919","volume":"61","author":"JT O\u2019Brien","year":"2004","unstructured":"O\u2019Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004;61:919.","journal-title":"Arch Neurol"},{"key":"6154_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1192\/bjp.bp.108.052050","volume":"194","author":"JT O\u2019Brien","year":"2009","unstructured":"O\u2019Brien JT, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Diagnostic accuracy of 123 I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry. 2009;194:34\u20139.","journal-title":"Br J Psychiatry"},{"key":"6154_CR38","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s00259-019-04324-5","volume":"46","author":"A Pilotto","year":"2019","unstructured":"Pilotto A, Schiano di Cola F, Premi E, Grasso R, Turrone R, Gipponi S, et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson\u2019s disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2019;46:1642\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6154_CR39","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s002590100571","volume":"28","author":"G Ransmayr","year":"2001","unstructured":"Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson\u2019s disease. Eur J Nucl Med Mol Imaging. 2001;28:1523\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6154_CR40","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/mds.22702","volume":"24","author":"F Roselli","year":"2009","unstructured":"Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A 123 I-FP-CIT SPECT study: DAT Levels and Neuropsychiatric Symptoms in DLB. Mov Disord. 2009;24:2097\u2013103.","journal-title":"Mov Disord"},{"key":"6154_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/mds.26327","volume":"31","author":"FJ Siepel","year":"2016","unstructured":"Siepel FJ, Dalen I, Gr\u00fcner R, Booij J, Br\u00f8nnick KS, Buter TC, et al. Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies: DAT scan in Dementia with Lewy Bodies. Mov Disord. 2016;31:118\u201325.","journal-title":"Mov Disord"},{"key":"6154_CR42","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1097\/RLU.0000000000000554","volume":"40","author":"TS Spehl","year":"2015","unstructured":"Spehl TS, Frings L, Hellwig S, Weiller C, H\u00fcll M, Meyer PT, et al. Role of semiquantitative assessment of regional binding potential in 123I-FP-CIT SPECT for the differentiation of frontotemporal dementia, dementia with Lewy bodies, and Alzheimer\u2019s dementia. Clin Nucl Med. 2015;40:e27\u201333.","journal-title":"Clin Nucl Med"},{"key":"6154_CR43","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/jnnp.2006.111666","volume":"78","author":"J-P Taylor","year":"2007","unstructured":"Taylor J-P, Colloby SJ, McKeith IG, Burn DJ, Williams D, Patterson J, et al. Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer\u2019s disease from dementia with Lewy bodies. J Neurol Neurosurg Amp Psychiatry. 2007;78:1069\u201371.","journal-title":"J Neurol Neurosurg Amp Psychiatry"},{"key":"6154_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13195-021-00792-w","volume":"13","author":"M van de Beek","year":"2021","unstructured":"van de Beek M, van Steenoven I, van der Zande JJ, Porcelijn I, Barkhof F, Stam CJ, et al. Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. Alzheimers Res Ther. 2021;13:53.","journal-title":"Alzheimers Res Ther"},{"key":"6154_CR45","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s00259-016-3312-x","volume":"43","author":"JJ van der Zande","year":"2016","unstructured":"van der Zande JJ, Booij J, Scheltens P, Raijmakers PGHM, Lemstra AW. [123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2016;43:1060\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6154_CR46","doi-asserted-by":"publisher","first-page":"102062","DOI":"10.1016\/j.nicl.2019.102062","volume":"25","author":"JJ van der Zande","year":"2020","unstructured":"van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens Ph, Booij J, et al. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer\u2019s disease pathology: An 123I-FP-CIT SPECT study. NeuroImage Clin. 2020;25:102062.","journal-title":"NeuroImage Clin"},{"key":"6154_CR47","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1212\/01.WNL.0000123248.39847.1D","volume":"62","author":"Z Walker","year":"2004","unstructured":"Walker Z, Costa DC, Walker RWH, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;62:1568\u201372.","journal-title":"Neurology"},{"key":"6154_CR48","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.2967\/jnumed.112.114025","volume":"54","author":"M Ziebell","year":"2013","unstructured":"Ziebell M, Andersen BB, Pinborg LH, Knudsen GM, Stokholm J, Thomsen G, et al. Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med. 2013;54:1072\u20136.","journal-title":"J Nucl Med"},{"key":"6154_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10072-003-0110-6","volume":"24","author":"R Ceravolo","year":"2003","unstructured":"Ceravolo R, Volterrani D, Gambaccini G, Rossi C, Logi C, Manca G, et al. Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer?s disease. Neurol Sci. 2003;24:162\u20133.","journal-title":"Neurol Sci"},{"key":"6154_CR50","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/MNM.0b013e328343d4ec","volume":"32","author":"PM Kemp","year":"2011","unstructured":"Kemp PM, Clyde K, Holmes C. Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies: a retrospective study. Nucl Med Commun. 2011;32:298\u2013302.","journal-title":"Nucl Med Commun"},{"key":"6154_CR51","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.nicl.2018.09.012","volume":"20","author":"JJ Lloyd","year":"2018","unstructured":"Lloyd JJ, Petrides G, Donaghy PC, Colloby SJ, Attems J, O\u2019Brien JT, et al. A new visual rating scale for Ioflupane imaging in Lewy body disease. NeuroImage Clin. 2018;20:823\u20139.","journal-title":"NeuroImage Clin"},{"key":"6154_CR52","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2967\/jnumed.119.239418","volume":"61","author":"DD Maltais","year":"2020","unstructured":"Maltais DD, Jordan LG, Min H-K, Miyagawa T, Przybelski SA, Lesnick TG, et al. Confirmation of 123 I-FP-CIT SPECT Quantification methods in dementia with Lewy bodies and other neurodegenerative disorders. J Nucl Med. 2020;61:1628\u201335.","journal-title":"J Nucl Med"},{"key":"6154_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2017.11.039","volume":"385","author":"N Nicastro","year":"2018","unstructured":"Nicastro N, Burkhard PR, Garibotto V. Scan without evidence of dopaminergic deficit (SWEDD) in degenerative parkinsonism and dementia with Lewy bodies: a prospective study. J Neurol Sci. 2018;385:17\u201321.","journal-title":"J Neurol Sci"},{"key":"6154_CR54","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1192\/bjp.2020.234","volume":"218","author":"G Roberts","year":"2021","unstructured":"Roberts G, Donaghy PC, Lloyd J, Durcan R, Petrides G, Colloby SJ, et al. Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. Br J Psychiatry. 2021;218:276\u201382.","journal-title":"Br J Psychiatry"},{"key":"6154_CR55","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1017\/S0033291718000995","volume":"49","author":"AJ Thomas","year":"2019","unstructured":"Thomas AJ, Donaghy P, Roberts G, Colloby SJ, Barnett NA, Petrides G, et al. Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychol Med. 2019;49:396\u2013402.","journal-title":"Psychol Med"},{"key":"6154_CR56","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","volume":"78","author":"Z Walker","year":"2007","unstructured":"Walker Z, Jaros E, Walker RWH, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Amp Psychiatry. 2007;78:1176\u201381.","journal-title":"J Neurol Neurosurg Amp Psychiatry"},{"key":"6154_CR57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1192\/bjp.bp.114.148643","volume":"206","author":"Z Walker","year":"2015","unstructured":"Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, et al. Clinical usefulness of dopamine transporter SPECT imaging with 123 I-FP-CIT in patients with possible dementia with Lewy bodies: Randomised study. Br J Psychiatry. 2015;206:145\u201352.","journal-title":"Br J Psychiatry"},{"key":"6154_CR58","doi-asserted-by":"publisher","first-page":"116821","DOI":"10.1016\/j.jns.2020.116821","volume":"414","author":"T Miyamoto","year":"2020","unstructured":"Miyamoto T, Miyamoto M, Numahata K, Onoue H, Akaiwa Y, Sairenchi T. Reduced dopamine transporter binding predicts early transition to Lewy body disease in Japanese patients with idiopathic rapid eye movement sleep behavior disorder. J Neurol Sci. 2020;414:116821.","journal-title":"J Neurol Sci"},{"key":"6154_CR59","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/jnnp-2020-324606","volume":"92","author":"FPM Oliveira","year":"2021","unstructured":"Oliveira FPM, Walker Z, Walker RWH, Attems J, Castanheira JC, Silva \u00c2, et al. 123 I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson\u2019s disease and Alzheimer\u2019s disease: a new quantitative analysis of autopsy confirmed cases. J Neurol Neurosurg Psychiatry. 2021;92:662\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6154_CR60","doi-asserted-by":"publisher","first-page":"709215","DOI":"10.3389\/fnagi.2021.709215","volume":"13","author":"P-Y Chiu","year":"2021","unstructured":"Chiu P-Y, Wei C-Y, Hung G-U, Wu S-L. Motor dysfunction questionnaire and dopamine transporter imaging composite scale improve differentiating dementia with Lewy bodies from Alzheimer\u2019s disease with motor dysfunction. Front Aging Neurosci. 2021;13:709215.","journal-title":"Front Aging Neurosci"},{"key":"6154_CR61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/RLU.0000000000000602","volume":"40","author":"A Del Sole","year":"2015","unstructured":"Del Sole A, Perini G, Lecchi M, Mariani C, Lucignani G, Clerici F. correlation Between 123I-FP-CIT brain SPECT and Parkinsonism in dementia with Lewy bodies: caveat for clinical use. Clin Nucl Med. 2015;40:32\u20135.","journal-title":"Clin Nucl Med"},{"key":"6154_CR62","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1017\/S0033291717003956","volume":"48","author":"PC Donaghy","year":"2018","unstructured":"Donaghy PC, Taylor J-P, O\u2019Brien JT, Barnett N, Olsen K, Colloby SJ, et al. Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies. Psychol Med. 2018;48:2384\u201390.","journal-title":"Psychol Med"},{"key":"6154_CR63","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/gps.5100","volume":"34","author":"R Durcan","year":"2019","unstructured":"Durcan R, Donaghy PC, Barnett NA, Olsen K, Yarnall AJ, Taylor J-P, et al. Prevalence and severity of symptoms suggestive of gastroparesis in prodromal dementia with Lewy bodies. Int J Geriatr Psychiatry. 2019;34:990\u20138.","journal-title":"Int J Geriatr Psychiatry"},{"key":"6154_CR64","doi-asserted-by":"publisher","first-page":"672956","DOI":"10.3389\/fnagi.2021.672956","volume":"13","author":"N Hansen","year":"2021","unstructured":"Hansen N, Lange C, Tim\u00e4us C, Wiltfang J, Bouter C. Assessing nigrostriatal dopaminergic pathways via 123I-FP-CIT SPECT in dementia with Lewy bodies in a psychiatric patient cohort. Front Aging Neurosci. 2021;13:672956.","journal-title":"Front Aging Neurosci"},{"key":"6154_CR65","doi-asserted-by":"publisher","first-page":"e002642","DOI":"10.1136\/bmjopen-2013-002642","volume":"3","author":"FJ Siepel","year":"2013","unstructured":"Siepel FJ, Rongve A, Buter TC, Beyer MK, Ballard CG, Booij J, et al. (123 I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. BMJ Open. 2013;3:e002642.","journal-title":"BMJ Open"},{"key":"6154_CR66","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/jnnp.73.2.134","volume":"73","author":"Z Walker","year":"2002","unstructured":"Walker Z. Differentiation of dementia with Lewy bodies from Alzheimer\u2019s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73:134\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6154_CR67","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/brain\/awh725","volume":"129","author":"P Tiraboschi","year":"2006","unstructured":"Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer\u2019s disease in early-stage dementia? Brain. 2006;129:729\u201335.","journal-title":"Brain"},{"key":"6154_CR68","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","volume":"6","author":"I McKeith","year":"2007","unstructured":"McKeith I, O\u2019Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305\u201313.","journal-title":"Lancet Neurol"},{"key":"6154_CR69","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1212\/WNL.0000000000011699","volume":"96","author":"E Howard","year":"2021","unstructured":"Howard E, Irwin DJ, Rascovsky K, Nevler N, Shellikeri S, Tropea TF, et al. Cognitive profile and markers of Alzheimer disease\u2013type pathology in patients with Lewy body dementias. Neurology. 2021;96:e1855\u201364.","journal-title":"Neurology"},{"key":"6154_CR70","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1093\/brain\/awab218","volume":"144","author":"J Schumacher","year":"2021","unstructured":"Schumacher J, Gunter JL, Przybelski SA, Jones DT, Graff-Radford J, Savica R, et al. Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain. 2021;144:3212\u201325.","journal-title":"Brain"},{"key":"6154_CR71","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10072-010-0239-z","volume":"31","author":"G Treglia","year":"2010","unstructured":"Treglia G, Cason E, Gabellini A, Giordano A, Fagioli G. Recent developments in innervation imaging using iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body diseases. Neurol Sci. 2010;31:417\u201322.","journal-title":"Neurol Sci"},{"key":"6154_CR72","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10072-003-0103-5","volume":"24","author":"A Antonini","year":"2003","unstructured":"Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, et al. 123I-Ioflupane\/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson\u2019s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24:149\u201350.","journal-title":"Neurol Sci"},{"key":"6154_CR73","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94:743\u201355.","journal-title":"Neurology"},{"key":"6154_CR74","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/nan.12659","volume":"46","author":"DG Coughlin","year":"2020","unstructured":"Coughlin DG, Ittyerah R, Peterson C, Phillips JS, Miller S, Rascovsky K, et al. Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer\u2019s disease Neuropathol Appl Neurobiol. 2020;46:707\u201321.","journal-title":"Alzheimer\u2019s disease Neuropathol Appl Neurobiol"},{"key":"6154_CR75","doi-asserted-by":"publisher","first-page":"eabc8362","DOI":"10.1126\/scitranslmed.abc8362","volume":"13","author":"F Bernasconi","year":"2021","unstructured":"Bernasconi F, Blondiaux E, Potheegadoo J, Stripeikyte G, Pagonabarraga J, Bejr-Kasem H, et al. Robot-induced hallucinations in Parkinson\u2019s disease depend on altered sensorimotor processing in fronto-temporal network. Sci Transl Med. 2021;13:eabc8362.","journal-title":"Sci Transl Med"},{"key":"6154_CR76","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/jnnp.2010.234799","volume":"82","author":"G Fenelon","year":"2011","unstructured":"Fenelon G, Soulas T, de Langavant LC, Trinkler I, Bachoud-Levi A-C. Feeling of presence in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2011;82:1219\u201324.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6154_CR77","doi-asserted-by":"publisher","first-page":"38152","DOI":"10.1038\/srep38152","volume":"6","author":"PM Llorca","year":"2016","unstructured":"Llorca PM, Pereira B, Jardri R, Chereau-Boudet I, Brousse G, Misdrahi D, et al. Hallucinations in schizophrenia and Parkinson\u2019s disease: an analysis of sensory modalities involved and the repercussion on patients. Sci Rep. 2016;6:38152.","journal-title":"Sci Rep"},{"key":"6154_CR78","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3233\/JAD-150675","volume":"50","author":"A Mishima","year":"2015","unstructured":"Mishima A, Nihashi T, Ando Y, Kawai H, Kato T, Ito K, et al. Biomarkers Differentiating dementia with lewy bodies from other dementias: a meta-analysis. J Alzheimers Dis. 2015;50:161\u201374.","journal-title":"J Alzheimers Dis"},{"key":"6154_CR79","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s00259-016-3496-0","volume":"44","author":"K Yokoyama","year":"2017","unstructured":"Yokoyama K, Imabayashi E, Sumida K, Sone D, Kimura Y, Sato N, et al. Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT. Eur J Nucl Med Mol Imaging. 2017;44:366\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06154-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T04:05:33Z","timestamp":1684555533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06154-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6154"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06154-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}